Pharvaris Investor Relations Material
Latest events
Status Update
Pharvaris
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Pharvaris N.V.
Access all reports
Pharvaris N.V. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for rare diseases, particularly hereditary angioedema (HAE). The company specializes in creating oral bradykinin B2 receptor antagonists, offering alternatives to existing injected treatments. Its key developments include PHVS416, a soft capsule for on-demand use during acute HAE attacks, and PHVS719, an extended-release tablet aimed at preventing such attacks. Pharvaris operates primarily in the Netherlands, Switzerland, and the United States. The company is headquartered in Leiden, the Netherlands, and its shares are listed on the NASDAQ.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
PHVS
Country
🇺🇸 United States